S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:MIRM

Mirum Pharmaceuticals (MIRM) Stock Price, News & Analysis

$25.12
0.00 (0.00%)
(As of 03/28/2024 ET)
Today's Range
$25.06
$25.79
50-Day Range
$24.92
$29.93
52-Week Range
$21.83
$35.56
Volume
424,360 shs
Average Volume
597,991 shs
Market Capitalization
$1.18 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$52.11

Mirum Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.13 Rating Score
Upside/​Downside
107.4% Upside
$52.11 Price Target
Short Interest
Bearish
17.32% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.69
Upright™ Environmental Score
News Sentiment
0.52mentions of Mirum Pharmaceuticals in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$359,119 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.12) to $1.08 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.14 out of 5 stars

Medical Sector

189th out of 938 stocks

Pharmaceutical Preparations Industry

75th out of 425 stocks

MIRM stock logo

About Mirum Pharmaceuticals Stock (NASDAQ:MIRM)

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

MIRM Stock Price History

MIRM Stock News Headlines

Crypto Market Preps For Trillions Worth of Inflows!
Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.
Mirum Pharmaceuticals Inc (MIRM) Insider Sells Shares
A lot of people are making this costly mistake
You may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time.
MIRM Mar 2024 40.000 call
See More Headlines
Receive MIRM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mirum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
3/28/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:MIRM
Fax
N/A
Employees
264
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$52.11
High Stock Price Target
$72.00
Low Stock Price Target
$35.00
Potential Upside/Downside
+105.1%
Consensus Rating
Buy
Rating Score (0-4)
3.13
Research Coverage
8 Analysts

Profitability

Net Income
$-163,410,000.00
Pretax Margin
-87.15%

Debt

Sales & Book Value

Annual Sales
$186.37 million
Book Value
$5.33 per share

Miscellaneous

Free Float
35,694,000
Market Cap
$1.19 billion
Optionable
Optionable
Beta
1.16
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Christopher PeetzMr. Christopher Peetz (Age 45)
    CEO & Director
    Comp: $1.09M
  • Mr. Peter Radovich M.B.A. (Age 46)
    Ph.D., COO & President
    Comp: $732.15k
  • Dr. Pamela Vig Ph.D. (Age 53)
    Chief Scientific Officer & Head of Research
    Comp: $678.2k
  • Ms. Lara Longpre MBA (Age 54)
    MSC, Chief Development Officer
    Comp: $678.2k
  • Mr. Eric H. Bjerkholt M.B.A. (Age 64)
    Chief Financial Officer
  • Andrew McKibben
    Vice President of Investor Relations and Finance
  • Mr. Paul K. Ross
    Chief Compliance Officer
  • Ms. Erin Campany (Age 56)
    Senior Vice President of Human Resources
  • Dr. Ian Clements Ph.D. (Age 55)
    Consultant
    Comp: $649.1k
  • Ms. Vinita P. Kumar
    Senior vice President of Quality

MIRM Stock Analysis - Frequently Asked Questions

Should I buy or sell Mirum Pharmaceuticals stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mirum Pharmaceuticals in the last twelve months. There are currently 7 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" MIRM shares.
View MIRM analyst ratings
or view top-rated stocks.

What is Mirum Pharmaceuticals' stock price target for 2024?

8 brokers have issued 12-month price targets for Mirum Pharmaceuticals' shares. Their MIRM share price targets range from $35.00 to $72.00. On average, they expect the company's stock price to reach $52.11 in the next year. This suggests a possible upside of 107.4% from the stock's current price.
View analysts price targets for MIRM
or view top-rated stocks among Wall Street analysts.

How have MIRM shares performed in 2024?

Mirum Pharmaceuticals' stock was trading at $29.52 at the start of the year. Since then, MIRM shares have decreased by 14.9% and is now trading at $25.12.
View the best growth stocks for 2024 here
.

When is Mirum Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our MIRM earnings forecast
.

How were Mirum Pharmaceuticals' earnings last quarter?

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) posted its quarterly earnings data on Wednesday, February, 28th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by $0.32. The firm earned $69.55 million during the quarter, compared to the consensus estimate of $66.73 million. Mirum Pharmaceuticals had a negative trailing twelve-month return on equity of 66.24% and a negative net margin of 86.33%.

What ETFs hold Mirum Pharmaceuticals' stock?

ETFs with the largest weight of Mirum Pharmaceuticals (NASDAQ:MIRM) stock in their portfolio include Simplify Propel Opportunities ETF (SURI).Virtus LifeSci Biotech Products ETF (BBP).

What guidance has Mirum Pharmaceuticals issued on next quarter's earnings?

Mirum Pharmaceuticals updated its FY 2023 earnings guidance on Monday, January, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $186.0 million-$188.0 million, compared to the consensus revenue estimate of $185.4 million.

What other stocks do shareholders of Mirum Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mirum Pharmaceuticals investors own include Pfizer (PFE), Fulcrum Therapeutics (FULC), OPKO Health (OPK), Vaxart (VXRT), Advanced Micro Devices (AMD), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), Trevena (TRVN), VBI Vaccines (VBIV) and Dynavax Technologies (DVAX).

When did Mirum Pharmaceuticals IPO?

Mirum Pharmaceuticals (MIRM) raised $75 million in an initial public offering on Thursday, July 18th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Citigroup, Evercore ISI and Guggenheim Securities served as the underwriters for the IPO and Raymond James and Roth Capital Partners were co-managers.

Who are Mirum Pharmaceuticals' major shareholders?

Mirum Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Frazier Life Sciences Management L.P. (13.93%), Eventide Asset Management LLC (5.71%), Vanguard Group Inc. (5.31%), Vanguard Group Inc. (5.31%), Cadian Capital Management LP (4.15%) and Price T Rowe Associates Inc. MD (2.50%). Insiders that own company stock include Christopher Peetz, Eric Bjerkholt, Ian Clements, James E Flynn, John A Maurer, Jolanda Howe, Lara Longpre, Michael G Grey, Niall O'donnell, Pamela Vig, Patrick J Heron and Peter Radovich.
View institutional ownership trends
.

How do I buy shares of Mirum Pharmaceuticals?

Shares of MIRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MIRM) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners